Ovid Therapeutics Inc. (OVID): history, ownership, mission, how it works & makes money

A Brief History of Ovid Therapeutics Inc. (OVID)

Founding and Initial Public Offering

Ovid Therapeutics Inc. was founded in 2014 by Dr. Jeremy Levin, who previously served as CEO of Teva Pharmaceutical Industries. The company, headquartered in New York City, focuses on developing innovative therapies for rare neurological disorders. In 2017, Ovid Therapeutics completed its initial public offering (IPO), raising approximately $126 million at a share price of $15.

Key Products and Development Pipeline

Ovid Therapeutics is primarily known for its lead product candidate, OV101 (gaboxadol), which is being developed as a potential treatment for patients with Angelman syndrome and other neurodevelopmental disorders. The company's pipeline includes:

• OV101: Currently in Phase 3 clinical trials for Angelman syndrome.
• OV935: Investigated for rare epilepsy syndromes, completed Phase 2 studies.
• OV-329: Aiming for the treatment of epilepsy, currently in early clinical development.

Financial Performance Metrics

As of Q2 2023, Ovid Therapeutics reported financial data as follows:

Partnerships and Collaborations

Ovid Therapeutics has established collaborations with various organizations to enhance its research and development capabilities. Notable partnerships include:

• Collaboration with Sarepta Therapeutics for gene therapy platforms.
• Research agreement with UCLA for the development of new treatment strategies.
• Partnership with National Institute of Health (NIH) for studies related to neurodevelopmental disorders.

Recent Developments and Market Position

As of 2023, Ovid Therapeutics continues to make strides in clinical trials and regulatory submissions. The company aims to submit a New Drug Application (NDA) for OV101 by the end of 2023. Market interest in their products has been bolstered by the growing focus on rare diseases and potential therapies in the neurology sector.

Stock Performance

Ovid Therapeutics' stock has experienced fluctuations in the market. As of October 2023, the stock price is approximately $3.25, reflecting a year-to-date decline of about 45%.

Future Outlook

Looking forward, Ovid Therapeutics aims to expand its pipeline and continue clinical development for its existing candidates. The market potential for treatments targeting rare neurological conditions remains significant, with an increasing prevalence of such disorders globally.

A Who Owns Ovid Therapeutics Inc. (OVID)

Major Shareholders

Ovid Therapeutics Inc. (OVID) is publicly traded on the NASDAQ under the ticker symbol OVID. Ownership of the company is divided among institutional investors, individual investors, and company insiders.

Key Institutional Investors

The institutional ownership of Ovid Therapeutics is significant. Major investment funds and entities hold large stakes in the company.

Insider Transactions

Insider ownership plays a critical role in corporate governance and alignment of interests between management and shareholders.

Market Capitalization

The market capitalization of Ovid Therapeutics serves as an indicator of the company's total equity value.

Market Capitalization: $102 million

Stock Performance

Ovid Therapeutics has experienced fluctuations in stock price reflective of market sentiments and company developments.

Recent Financial Data

Financial performance details provide insight into the company's operational health and growth potential.

Conclusion on Ownership Structure

The ownership of Ovid Therapeutics Inc. comprises a mix of institutional, individual, and insider shareholders. The significant percentage of institutional ownership indicates a strong level of interest from large investment entities.

Ovid Therapeutics Inc. (OVID) Mission Statement

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with rare neurological disorders. The company aims to transform the standard of care through its proprietary drug development programs.

Core Mission

The mission statement of Ovid Therapeutics emphasizes its commitment to

• Delivering novel therapeutics for patients with serious neurological conditions.
• Championing scientific innovation and collaboration.
• Prioritizing patient-centric approaches in drug development.

Strategic Goals

Ovid Therapeutics pursues several strategic goals that reflect its mission, including:

• Advancement of pipeline products: Focus on clinical development of therapies targeting conditions like Angelman syndrome.
• Partnerships and collaborations: Engaging with academic institutions and other biotech entities to enhance research capabilities.
• Regulatory excellence: Navigating the FDA approval process efficiently for timely patient access to therapies.

Financial Overview

The financial health of Ovid Therapeutics is critical in supporting its mission. As of Q2 2023, the financial data includes:

Research Initiatives

Ovid Therapeutics has identified several key research initiatives which are tightly aligned with its mission:

• Angelman Syndrome Program: Clinical trials for OV101, aimed at a specific neurological target.
• Next Generation Treatments: Exploring proprietary compounds that address broader neurological disorders.
• Patient Engagement: Integrating patient feedback into the development process to enhance relevance of therapies.

Corporate Values

The corporate values that guide Ovid Therapeutics reflect its mission-driven approach:

• Integrity: Upholding transparency and ethical standards in every aspect of the business.
• Innovation: Fostering a culture of creativity and scientific inquiry.
• Collaboration: Building strong partnerships with stakeholders to drive collective success.

Market Positioning

As of October 2023, Ovid Therapeutics holds a distinctive position in the biopharmaceutical market:

• Market Cap: Approximately $150 million.
• Primary Competitors: Include Amgen, Ionis Pharmaceuticals, and Zogenix in the rare neurological disorder space.
• Pipeline Valuation: Estimated potential market for OV101 could exceed $1 billion upon successful approval and launch.

How Ovid Therapeutics Inc. (OVID) Works

Corporate Overview

Ovid Therapeutics Inc. is a biopharmaceutical company specializing in the development of therapies for rare neurological disorders. The company is focused on leveraging its expertise in genetic and molecular biology to address unmet medical needs.

Financial Performance

As of the third quarter of 2023, Ovid Therapeutics reported the following financial figures:

Product Pipeline

Ovid's pipeline includes several key programs for the treatment of rare epilepsy syndromes and other neurological conditions. The primary investigational drugs include:

Key Partnerships

Ovid Therapeutics has established strategic collaborations to enhance its research capabilities and market access. Notable partnerships include:

• Partnership with Takeda Pharmaceutical Company for the development of therapies for neurodevelopmental disorders.
• Collaboration with the Epilepsy Foundation to raise awareness and improve treatment options for epilepsy patients.
• Research agreement with the University of California to explore novel therapeutic targets in rare neurological diseases.

Market Position

Ovid Therapeutics operates within a competitive landscape characterized by numerous biotech firms focusing on neurological disorders. The total addressable market for epilepsy treatments is projected to exceed $12 billion by 2025.

Stock Information

As of October 2023, Ovid Therapeutics (NASDAQ: OVID) has the following stock market data:

Regulatory Environment

Ovid operates in a heavily regulated industry. To date, the company has submitted several Investigational New Drug (IND) applications to the FDA. The regulatory approval process generally spans multiple phases:

• Phase 1: Safety Trials
• Phase 2: Efficacy Trials
• Phase 3: Large-Scale Trials for Confirmation

Research and Development Strategy

Ovid's R&D strategy emphasizes leveraging genetic insights to develop targeted therapies. Historical R&D spending has averaged 70% of total expenses, reflecting its commitment to innovation in neuroscience.

How Ovid Therapeutics Inc. (OVID) Makes Money

Product Revenue

Ovid Therapeutics focuses on developing innovative medicines for people with neurologic disorders. One of the key products generating revenue is OV935, which targets the treatment of Dravet syndrome and other epileptic disorders. The expected market size for Dravet syndrome treatments in the U.S. is approximately $300 million by 2026.

Collaboration Agreements

Ovid Therapeutics has entered into several collaboration agreements that enhance its revenue-generating capabilities. For instance, in 2020, Ovid entered into a collaboration with Takeda Pharmaceutical Company Limited, which includes milestone payments and royalties on commercial sales. The agreement could yield up to $124 million in potential milestones and royalties.

Grants and Funding

Ovid has received significant funding through various grants aimed at neurodevelopmental disorders. In 2021, it was reported that Ovid received a grant of $2.7 million from the NINDS (National Institute of Neurological Disorders and Stroke) to support research for its drug candidates. This funding boosts Ovid's ability to conduct clinical trials without impacting its capital significantly.

Clinical Trials and Development

The company allocates a substantial portion of its expenditures on research and development to advance its pipeline. In the fiscal year 2022, Ovid reported R&D expenses of approximately $40 million, which is essential for its ongoing clinical trials and product development.

Table of Financial Overview

Market Capitalization

As of October 2023, Ovid Therapeutics holds a market capitalization of approximately $240 million. This financial metric reflects investor confidence and the company's potential for future growth.

Future Revenue Streams

Looking ahead, Ovid is anticipating additional revenue streams from its ongoing clinical trials and potential new product approvals. The company has projected that its pipeline could contribute up to $500 million in annual revenue by mid-decade if favorable outcomes from clinical trials are achieved.

Stock Performance

The stock price of Ovid Therapeutics has shown volatility, but recent trends indicate a growth trajectory. The stock was priced at around $5.60 per share as of the latest trading session, reflecting a year-to-date increase of approximately 30%.

Partnerships for Expansion

Strategic partnerships are integral to Ovid's business model. The partnership with Takeda is particularly noteworthy, as it allows for shared development costs and access to Takeda's extensive distribution network, potentially enhancing market penetration and revenue generation capabilities.

Regulatory Milestones

The company has been strategically focusing on achieving regulatory milestones. Successful completion of Phase 3 trials could lead to FDA approval, which would significantly impact revenue projections, with estimates suggesting potential peak sales reaching over $300 million for key product candidates.

Investor Relations

Ovid maintains a robust relationship with its investors, providing regular updates on clinical trials, financial health, and growth strategies. The company aims to instill confidence through transparency and strategic foresight.

Conclusion

Ovid Therapeutics is positioned in the niche market of neurological disorders, relying on product revenue, collaboration agreements, and strategic funding to drive its business model. The company's focus on innovative therapies and robust clinical pipelines provides a foundation for future financial success.